Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06634667 | Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06618391 | Local Injection and Systemic Therapy in the Treatment of NSCLC. | not yet recruiting | Phase 2 | 84 | Henan Cancer HospitalOTHER_GOV | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06620822 | Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial | not yet recruiting | Phase 2 | 296 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06614231 | Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06537297 | Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06604351 | Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction(Example) | not yet recruiting | Phase 2 | 39 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06475755 | Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC | not yet recruiting | Phase 2 | 178 | Tang-Du HospitalOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06454890 | Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 1 / Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 0 | Jun 12, 2024 | clinicaltrials |
| NCT06452433 | Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. | not yet recruiting | Phase 2 | 91 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 11, 2024 | clinicaltrials |
| NCT06434740 | A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC | not yet recruiting | Phase 2 | 37 | Sir Run Run Shaw HospitalOTHER | 0 | May 30, 2024 | clinicaltrials |
| NCT06436144 | Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC | not yet recruiting | Phase 2 | 93 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | May 30, 2024 | clinicaltrials |
| NCT06414915 | Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation | not yet recruiting | Phase 2 | 29 | National Cancer Center, ChinaOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT05859217 | A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)(Cabatezo-1) | not yet recruiting | Phase 2 | 40 | Jun Zhang, MD, PhDOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06336954 | Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure | not yet recruiting | Phase 2 | 40 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Mar 29, 2024 | clinicaltrials |
| NCT06335355 | A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients | not yet recruiting | Phase 2 / Phase 3 | 401 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06299371 | Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations | not yet recruiting | Phase 2 | 36 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT06282536 | Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial | not yet recruiting | Phase 2 | 20 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06221462 | Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer(PRIORITY) | not yet recruiting | Phase 2 | 30 | Ningbo No.2 HospitalOTHER | 0 | Jan 25, 2024 | clinicaltrials |
| NCT06198907 | Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)(JACKPOT33) | not yet recruiting | Phase 2 | 69 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06185400 | RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | not yet recruiting | Phase 2 | 108 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Dec 29, 2023 | clinicaltrials |
| NCT06182761 | A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer(WUKONG-9) | not yet recruiting | Phase 2 | 45 | Shanghai Zhongshan HospitalOTHER | 0 | Dec 27, 2023 | clinicaltrials |
| NCT06109402 | Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 160 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06142617 | A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. | not yet recruiting | Phase 2 | 37 | Peking Union Medical College HospitalOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06028633 | Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients | not yet recruiting | Phase 2 | 28 | Peking University First HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05891080 | Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial | not yet recruiting | Phase 2 | 124 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05778149 | Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation | not yet recruiting | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 21, 2023 | clinicaltrials |
| NCT05597800 | Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome(LUNGVIR) | not yet recruiting | Phase 2 | 105 | Universita di VeronaOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05548504 | Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC(HERAN2) | not yet recruiting | Phase 2 | 182 | Odense University HospitalOTHER | 0 | Sep 21, 2022 | clinicaltrials |
| NCT05186506 | A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 152 | Sichuan UniversityOTHER | 0 | Jan 11, 2022 | clinicaltrials |
| NCT05132985 | Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma | not yet recruiting | Phase 2 | 45 | Liaoning Cancer Hospital & InstituteOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT04846634 | Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)(ALTER-L043) | not yet recruiting | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT04153734 | Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC(Evolution) | not yet recruiting | Phase 2 | 21 | Kobe Minimally Invasive Cancer CenterOTHER | 0 | Nov 6, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Oct 10, 2024source: clinicaltrials